Hepatic Arterial Iodine-131–Labeled Metuximab Injection Combined with Chemoembolization for Unresectable Hepatocellular Carcinoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNRC-12002921

Enrollment

Unknown

Registered

2012-09-24

Start date

2009-02-02

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCC

Interventions

licartin group:Licartin with conventional TACE

TACE group:conventional TACE

Eligibility

Sex/Gender

All

Age

12 Years to 87 Years

Inclusion criteria

Inclusion criteria: patients with advanced HCCwilling to enroll into this trail.

Exclusion criteria

Exclusion criteria: 1. Allergic reactions to biological agents, hypersensitiveness; 2. Pregnancy and breast-feeding women; 3. The initial skin test-positive patients for Metuximab antibody; 4. Patients with brain metastases; 5. Patients with hypothyroidism; 6. Expected survival <1 month.

Design outcomes

Primary

Measure	Time frame
survival time;tumor react to treatment;toxic and adverse event;	—

Countries

China

Contacts

Public ContactQing He

tonyhe11@sina.com+86 15928987207

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026